|1.||Shibayama, Hiroharu: 2 articles (06/2012 - 03/2008)|
|2.||Matsunami, Maho: 1 article (06/2012)|
|3.||Nakanishi, Hiroki: 1 article (06/2012)|
|4.||Kawabata, Atsufumi: 1 article (06/2012)|
|5.||Okubo, Kazumasa: 1 article (06/2012)|
|6.||Iwaki, Masahiro: 1 article (03/2008)|
|7.||Hisama, Masayoshi: 1 article (03/2008)|
|8.||Matsuda, Sanae: 1 article (03/2008)|
|9.||Ohtsuki, Mamitaro: 1 article (03/2008)|
|1.||Melanoma (Melanoma, Malignant)
03/01/2008 - "We investigated the inhibitory effects of a novel amphiphilic ascorbic derivative, disodium isostearyl 2-O-L-ascorbyl phosphate (VCP-IS-2Na), synthesized from a hydrophilic ascorbic derivative, sodium-2-O-L-ascorbyl phosphate (VCP-Na), on melanogenesis in cultured human melanoma cells, normal human melanocytes, and three-dimensional cultured human skin models. "
03/01/2008 - "VCP-IS-2Na also significantly suppressed the cellular tyrosinase activity of melanoma cells and melanocytes. "
03/01/2008 - "Melanin synthesis in melanoma cells treated with VCP-IS-2Na at 300 muM and melanocytes treated with VCP-IS-2Na at 100 muM decreased to 23% and 52% of that in non-treated cells, respectively, and the cell viability was not affected. "
06/01/2012 - "Topical application of disodium isostearyl 2-O-L-ascorbyl phosphate, an amphiphilic ascorbic acid derivative, reduces neuropathic hyperalgesia in rats."
06/01/2012 - "Therefore, we evaluated the effects of intraplantar (i.pl.) administration of ascorbic acid or topical application of disodium isostearyl 2-O-L-ascorbyl phosphate (DI-VCP), a skin-permeable ascorbate derivative on hyperalgesia induced by NaHS, an H(2) S donor, and on neuropathic hyperalgesia. "
|1.||Monophenol Monooxygenase (Tyrosinase)
|3.||Ascorbic Acid (Vitamin C)
|4.||sodium bisulfide (NaHS)